The Total Remission Rate of CAR-T Hodgkin Lymphoma Was 78%

The Total Remission Rate of CAR-T Hodgkin Lymphoma Was 78%

• Classical Hodgkin lymphoma (cHL) is a malignant lymphoid disease and the most common subtype of lymphoma. Statistics show that about 93,000 people in China are diagnosed with lymphoma each year.

• Although cHL can be cured, most patients experience disease relapse after first-line treatment, becoming difficult to treat with poor prognosis, leaving a significant unmet medical need.

• In recent years, CAR-T cell immunotherapy has made breakthrough progress in the field of hematologic malignancies as a revolutionary treatment. However, issues such as production costs, preparation time, and safety concerns associated with the need for “personalized manufacturing” have limited its accessibility. Developing an “off-the-shelf” CAR-T cell therapy has become an important research direction.

Off-the-Shelf CAR-T

Recently, the “off-the-shelf” CAR-T therapy TT11X achieved positive results in a clinical study treating patients with relapsed or refractory (R/R) cHL.

• Data showed that TT11X achieved an overall response rate of 78% in treating previously multi-line treated cHL patients.

TT11X is an off-the-shelf allogeneic CAR-T therapy that integrates the CD30 CAR into highly specific T cells (VSTs) and delivers them into an allogeneic environment, primarily for treating relapsed or refractory CD30-positive lymphomas.

In the reported trial, 18 previously treated R/R cHL patients received TT11X treatment.

The results showed:

1. In the trial, 14 patients achieved an objective response, with an objective response rate of 78%.

2. 7 patients achieved a complete response, and another 7 patients achieved a partial response, with higher doses improving clinical responses.

3. In terms of safety, TT11X demonstrated good tolerability, with no dose-limiting toxicities observed.

The trial data indicate that TT11X provides a potential effective and safe new treatment option for patients with CD30-positive Hodgkin lymphoma.

Reference Material

https://www.pharmaceutical-technology.com/news/tessa-therapeutics-hodgkins-lymphoma-car-t-therapy-shows-promising-phase-i-data/

Content Source:好医友